losartan has been researched along with Atrial Fibrillation in 61 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 9.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF." | 9.12 | Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. ( Dai, Y; Dalal, D; Dong, J; Lan, X; Ling, Z; Liu, D; Liu, Z; Luo, K; She, Q; Su, L; Woo, K; Wu, J; Yin, Y, 2006) |
| "The purpose of the present study was to evaluate the clinical efficacy of perindopril or losartan in combination with low-dose amiodarone on maintenance of sinus rhythm in patients with idiopathic paroxysmal atrial fibrillation (PAF)." | 9.12 | [Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation]. ( Dai, Y; Lan, XB; Ling, ZY; Liu, ZC; Luo, KL; Su, L; Wu, JJ; Yang, XY; Yin, YH, 2006) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 9.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 9.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 9.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| " The purpose of this article is to review post hoc sub-analyses of LIFE study data and other clinical studies that offer some insight into possible treatment-related differences contributing to the superior stroke outcome of losartan versus atenolol beyond blood pressure reduction." | 8.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis." | 7.77 | Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011) |
| "Although amiodarone plus angiotensin II receptor blockers (ARBs) and catheter ablation may improve sinus rhythm maintenance of paroxysmal atrial fibrillation (AF), their clinical efficacies have not been compared." | 7.75 | Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. ( Lan, X; Ling, Z; Liu, Z; Su, L; Wu, J; Yang, X; Yin, Y; Zrenner, B, 2009) |
| "This study was designed to compare clinical efficacy of segmental pulmonary vein ablation (SPVI), amiodarone or amiodarone plus losartan on sinus rhythm maintenance in patients with lone paroxysmal atrial fibrillation (PAF)." | 7.74 | [Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study]. ( Chen, YQ; Lan, XB; Ling, ZY; Liu, D; Liu, ZC; Luo, KL; She, Q; Su, L; Wu, JJ; Yang, XY; Yin, YH; Zrenner, B, 2007) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 6.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| "Losartan has recently been reported to suppress atrial structural remodeling." | 5.35 | The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. ( Kawano, T; Nakaya, Y; Nakayasu, K; Nomura, M, 2008) |
| "We performed a prospective, randomized clinical study to assess whether prophylactic treatment with metoprolol or losartan, initiated soon after lung cancer surgery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperative atrial fibrillation." | 5.22 | Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. ( Bacchiani, G; Beggiato, M; Cardinale, D; Casiraghi, M; Cipolla, CM; Civelli, M; Colombo, A; Colombo, N; Lamantia, G; Meroni, CA; Salvatici, M; Sandri, MT; Spaggiari, L; Tedeschi, I; Veglia, F; Venturino, M, 2016) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| " The risk of new-onset AF was examined in relation to last in-treatment SBP before AF diagnosis or last in-study measurement in the absence of new AF in 8831 hypertensive patients with ECG left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline ECG, randomly assigned to losartan- or atenolol-based treatment." | 5.20 | Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Larstorp, AC; Okin, PM; Wachtell, K, 2015) |
| "Incident AF was examined in 518 black and 8,313 nonblack hypertensive patients with electrocardiographic left ventricular hypertrophy (LVH) with no history of AF in sinus rhythm on their baseline electrocardiogram, who were randomly assigned to losartan- or atenolol-based treatment." | 5.19 | Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Julius, S; Kjeldsen, SE; Okin, PM; Wachtell, K, 2014) |
| "The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment." | 5.17 | Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2013) |
| "In the Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study, a double-blinded, randomized, parallel-group study, 9193 hypertensive patients with electrocardiogram (ECG)-documented left ventricular hypertrophy (LVH), randomized to once-daily losartan- or atenolol-based antihypertensive therapy were followed for a mean of 4." | 5.16 | Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Okin, PM; Olsen, MH; Reims, HM; Wachtell, K, 2012) |
| " We examined whether PP predicted new-onset AF in comparison with other blood pressure components in the Losartan Intervention For Endpoint reduction in hypertension study, a double-blind, randomized (losartan versus atenolol), parallel-group study, including 9193 patients with hypertension and electrocardiographic left ventricular hypertrophy." | 5.16 | Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. ( Ariansen, I; Dahlöf, B; Devereux, RB; Gjesdal, K; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| " Patients were treated with losartan- or atenolol-based regimens and followed with serial ECGs annually which were used to determine HR and ECG left ventricular hypertrophy by Cornell product and Sokolow-Lyon voltage criteria." | 5.13 | Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Hille, DA; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2008) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 5.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| "The purpose of the present study was to evaluate the clinical efficacy of perindopril or losartan in combination with low-dose amiodarone on maintenance of sinus rhythm in patients with idiopathic paroxysmal atrial fibrillation (PAF)." | 5.12 | [Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation]. ( Dai, Y; Lan, XB; Ling, ZY; Liu, ZC; Luo, KL; Su, L; Wu, JJ; Yang, XY; Yin, YH, 2006) |
| "The purpose of this trial was to compare the long-term efficacy of low-dose amiodarone with losartan and perindopril (both combined with low-dose amiodarone) for the prevention of atrial fibrillation (AF) recurrence in patients with lone paroxysmal AF." | 5.12 | Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. ( Dai, Y; Dalal, D; Dong, J; Lan, X; Ling, Z; Liu, D; Liu, Z; Luo, K; She, Q; Su, L; Woo, K; Wu, J; Yin, Y, 2006) |
| "Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Hille, DA; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Wachtell, K, 2006) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy." | 5.11 | Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Wachtell, K, 2005) |
| "As part of the Losartan Intervention For End point reduction in hypertension (LIFE) study, 342 hypertensive patients with AF and LV hypertrophy were assigned to losartan- or atenolol-based therapy for 1,471 patient-years of follow-up." | 5.11 | Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. ( Aurup, P; Dahlöf, B; Devereux, RB; Gerdts, E; Hornestam, B; Ibsen, H; Julius, S; Kjeldsen, SE; Lehto, M; Lindholm, LH; Nieminen, MS; Olsen, MH; Rokkedal, J; Slotwiner, DJ; Wachtell, K, 2005) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| " The purpose of this article is to review post hoc sub-analyses of LIFE study data and other clinical studies that offer some insight into possible treatment-related differences contributing to the superior stroke outcome of losartan versus atenolol beyond blood pressure reduction." | 4.84 | Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. ( Dahlöf, B; Devereux, RB, 2007) |
| "The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy." | 4.82 | Implications of the LIFE trial. ( Lim, HS; Lip, GY; Nadar, S, 2003) |
| "To determine the role of angiotensin II (Ang II)/Ang II type 1 (AT(1)) receptor-coupled transforming growth factor (TGF)-β(1)/Smad signaling pathway in the AF-induced atrial fibrosis." | 3.77 | Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. ( Duan, DD; Gao, X; He, X; Lin, J; Ma, H; Peng, L; Wang, S; Zhu, Y, 2011) |
| "Baseline and third year ECG LVH and left atrial systolic diameter were examined in 663 patients in the Losartan Intervention For Endpoint reduction in hypertension echocardiographic substudy who were in sinus rhythm at baseline and had no history of atrial fibrillation." | 3.76 | Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. ( Dahlöf, B; Devereux, RB; Gerdts, E; Nieminen, MS; Oikarinen, L; Okin, PM; Wachtell, K, 2010) |
| "Although amiodarone plus angiotensin II receptor blockers (ARBs) and catheter ablation may improve sinus rhythm maintenance of paroxysmal atrial fibrillation (AF), their clinical efficacies have not been compared." | 3.75 | Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation. ( Lan, X; Ling, Z; Liu, Z; Su, L; Wu, J; Yang, X; Yin, Y; Zrenner, B, 2009) |
| "This study was designed to compare clinical efficacy of segmental pulmonary vein ablation (SPVI), amiodarone or amiodarone plus losartan on sinus rhythm maintenance in patients with lone paroxysmal atrial fibrillation (PAF)." | 3.74 | [Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study]. ( Chen, YQ; Lan, XB; Ling, ZY; Liu, D; Liu, ZC; Luo, KL; She, Q; Su, L; Wu, JJ; Yang, XY; Yin, YH; Zrenner, B, 2007) |
| "The Ang II/Rac1/STAT3 pathway is an important signaling pathway in the atrial myocardium to mediate atrial structural remodeling, and losartan and statin may be able to reverse Ang II-induced atrial structural remodeling in atrial fibrillation." | 3.74 | Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. ( Chiang, FT; Hsieh, CS; Hsu, KL; Hwang, JJ; Kuo, KT; Lai, LP; Lin, JL; Tsai, CT; Tseng, CD; Tseng, YZ, 2008) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| "Psoriasis has a similar prevalence in hypertensive patients as in the general population." | 2.79 | Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. ( Bang, CN; Devereux, RB; Gottlieb, AB; Køber, L; Okin, PM; Wachtell, K, 2014) |
| "Risk of stroke was increased for the first 30 days (HR 14." | 2.71 | Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. ( Dickstein, K; Lehto, M; Nieminen, MS; Snapinn, S; Swedberg, K, 2005) |
| "Hypertension is a powerful risk factor of atrial fibrillation (AF)." | 1.42 | Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats. ( Chishaki, A; Hirooka, Y; Inoue, S; Kishi, T; Mukai, Y; Nagayama, T; Sunagawa, K; Takase, S; Takemoto, M, 2015) |
| "Hypertension is the most frequent condition associated with atrial fibrillation (AF) and stroke, the most terrible complication of AF." | 1.39 | Can dabigatran improve blood pressure control? ( Barrios, V; Escobar, C, 2013) |
| "Atrial fibrillation recurrence is a main factor contributing to enlargement of the LA." | 1.35 | The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study. ( Chen, Y; Du, H; Lan, X; Ling, Z; Liu, Z; She, Q; Su, L; Wu, J; Yin, Y, 2008) |
| "Losartan has recently been reported to suppress atrial structural remodeling." | 1.35 | The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. ( Kawano, T; Nakaya, Y; Nakayasu, K; Nomura, M, 2008) |
| "Hypertension is strongly associated with increased risk of subsequent heart failure." | 1.35 | [Hypertension and the heart]. ( Andersen, NH; Svendsen, TL; Wachtell, K, 2009) |
| "Hypertension is related to an increased wall tension in the atria, resulting in increased stretch of the individual myocyte, which is one of the major stimuli for the remodeling process." | 1.34 | Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes. ( Frank, K; Müller-Ehmsen, J; Rana, OR; Reuter, H; Saygili, E; Schwinger, RH; Zobel, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (65.57) | 29.6817 |
| 2010's | 19 (31.15) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, R | 1 |
| Wan, J | 1 |
| He, Y | 1 |
| Gong, H | 1 |
| Xu, Z | 1 |
| Feng, J | 1 |
| Gao, J | 1 |
| Tian, Y | 1 |
| Xie, X | 1 |
| Zhao, J | 1 |
| Liu, CH | 1 |
| Sheng, Y | 1 |
| Cao, F | 1 |
| Okin, PM | 11 |
| Bang, CN | 3 |
| Wachtell, K | 17 |
| Hille, DA | 6 |
| Kjeldsen, SE | 12 |
| Dahlöf, B | 16 |
| Devereux, RB | 16 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Kim, HS | 1 |
| No, CW | 1 |
| Goo, SH | 1 |
| Cha, TJ | 1 |
| Køber, L | 1 |
| Gottlieb, AB | 1 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 1 |
| Julius, S | 6 |
| Sakamoto, T | 1 |
| Kudoh, T | 1 |
| Sakamoto, K | 1 |
| Matsui, K | 1 |
| Ogawa, H | 1 |
| Takeshita, K | 1 |
| Murohara, T | 1 |
| Nagayama, T | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Mukai, Y | 1 |
| Inoue, S | 1 |
| Takase, S | 1 |
| Takemoto, M | 1 |
| Chishaki, A | 1 |
| Sunagawa, K | 1 |
| Takii, E | 1 |
| Inage, T | 1 |
| Yoshida, T | 1 |
| Ohe, M | 1 |
| Gondo, T | 1 |
| Haraguchi, G | 1 |
| Ito, S | 1 |
| Kumanomido, J | 1 |
| Imaizumi, T | 1 |
| Fukuomoto, Y | 1 |
| Boman, K | 2 |
| Chen, XQ | 1 |
| Zhang, DL | 1 |
| Zhang, MJ | 1 |
| Guo, M | 1 |
| Zhan, YY | 1 |
| Liu, F | 1 |
| Jiang, WF | 1 |
| Zhou, L | 1 |
| Zhao, L | 1 |
| Wang, QX | 1 |
| Liu, X | 1 |
| Larstorp, AC | 2 |
| Cardinale, D | 1 |
| Sandri, MT | 1 |
| Colombo, A | 1 |
| Salvatici, M | 1 |
| Tedeschi, I | 1 |
| Bacchiani, G | 1 |
| Beggiato, M | 1 |
| Meroni, CA | 1 |
| Civelli, M | 1 |
| Lamantia, G | 1 |
| Colombo, N | 1 |
| Veglia, F | 1 |
| Casiraghi, M | 1 |
| Spaggiari, L | 1 |
| Venturino, M | 1 |
| Cipolla, CM | 1 |
| Liu, Z | 3 |
| Ling, Z | 3 |
| Su, L | 5 |
| Wu, J | 3 |
| Lan, X | 3 |
| Chen, Y | 1 |
| Du, H | 1 |
| She, Q | 3 |
| Yin, Y | 3 |
| Yang, X | 1 |
| Zrenner, B | 2 |
| Andersen, NH | 1 |
| Svendsen, TL | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Lindholm, LH | 6 |
| Nieminen, MS | 8 |
| Edelman, JM | 4 |
| Gerdts, E | 4 |
| Aurigemma, GP | 1 |
| Olsen, MH | 7 |
| Palmieri, V | 1 |
| Rokkedal, JE | 1 |
| Oikarinen, L | 1 |
| He, X | 1 |
| Gao, X | 1 |
| Peng, L | 1 |
| Wang, S | 1 |
| Zhu, Y | 1 |
| Ma, H | 1 |
| Lin, J | 1 |
| Duan, DD | 1 |
| Ariansen, I | 2 |
| Reims, HM | 1 |
| Gjesdal, K | 2 |
| Ibsen, H | 7 |
| Nadar, S | 1 |
| Lim, HS | 1 |
| Lip, GY | 1 |
| Borch-Johnsen, K | 1 |
| Snapinn, S | 2 |
| Diener, HC | 1 |
| Stöllberger, C | 1 |
| Slany, J | 1 |
| Brainin, M | 1 |
| Finsterer, J | 1 |
| Li, Y | 1 |
| Li, WM | 1 |
| Xue, JY | 1 |
| Han, W | 1 |
| Yang, SS | 1 |
| Gu, HY | 1 |
| Kizer, JR | 1 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 2 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Snapinn, SM | 1 |
| Harris, KE | 2 |
| Lehto, M | 3 |
| Dickstein, K | 1 |
| Swedberg, K | 1 |
| Hornestam, B | 2 |
| Slotwiner, DJ | 1 |
| Aurup, P | 1 |
| Rokkedal, J | 1 |
| Bourassa, MG | 1 |
| Sosunov, EA | 1 |
| Anyukhovsky, EP | 1 |
| Hefer, D | 1 |
| Rosen, TS | 1 |
| Danilo, P | 1 |
| Janse, MJ | 1 |
| Rosen, MR | 1 |
| Franklin, SS | 1 |
| Papademetriou, V | 1 |
| Ogimoto, A | 1 |
| Shigematsu, Y | 1 |
| Hara, Y | 1 |
| Ohtsuka, T | 1 |
| Miki, T | 1 |
| Higaki, J | 1 |
| Nattel, S | 1 |
| Kalus, JS | 1 |
| Coleman, CI | 1 |
| White, CM | 1 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Destro, M | 1 |
| Corradi, L | 1 |
| Zoppi, A | 1 |
| Fogari, E | 1 |
| Rinaldi, A | 1 |
| Chrysant, SG | 1 |
| Chrysant, GS | 1 |
| Baumgart, P | 2 |
| Yin, YH | 2 |
| Liu, ZC | 2 |
| Wu, JJ | 2 |
| Dai, Y | 2 |
| Lan, XB | 2 |
| Ling, ZY | 2 |
| Yang, XY | 2 |
| Luo, KL | 2 |
| Dalal, D | 1 |
| Liu, D | 2 |
| Luo, K | 1 |
| Woo, K | 1 |
| Dong, J | 1 |
| Liu, T | 1 |
| Li, G | 1 |
| Jern, S | 1 |
| Nagasawa, H | 1 |
| Inoue, H | 1 |
| Kanna, B | 1 |
| Gopalam, M | 1 |
| Saygili, E | 2 |
| Rana, OR | 1 |
| Reuter, H | 1 |
| Frank, K | 1 |
| Schwinger, RH | 1 |
| Müller-Ehmsen, J | 1 |
| Zobel, C | 1 |
| Nomura, M | 1 |
| Kawano, T | 1 |
| Nakayasu, K | 1 |
| Nakaya, Y | 1 |
| Chen, YQ | 1 |
| Tsai, CT | 1 |
| Lai, LP | 1 |
| Kuo, KT | 1 |
| Hwang, JJ | 1 |
| Hsieh, CS | 1 |
| Hsu, KL | 1 |
| Tseng, CD | 1 |
| Tseng, YZ | 1 |
| Chiang, FT | 1 |
| Lin, JL | 1 |
| Yildiz, A | 1 |
| Yigit, Z | 1 |
| Okcun, B | 1 |
| Baskurt, M | 1 |
| Ortak, K | 1 |
| Kaya, A | 1 |
| Kucukoglu, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for losartan and Atrial Fibrillation
| Article | Year |
|---|---|
Implications of the LIFE trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillati | 2006 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2006 |
[Electrocardiographic findings].
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Clinical Trials as Topic; Electrocardi | 2006 |
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2007 |
21 trials available for losartan and Atrial Fibrillation
| Article | Year |
|---|---|
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Confidence Intervals; Death, Sudden, C | 2013 |
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Double- | 2014 |
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Black People; Female; Humans; Hypertension; Hype | 2014 |
Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Dose-Response Relationship, Drug | 2014 |
Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Biologic | 2016 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Double-Blind Method; E | 2015 |
Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Incidence; Losartan; Lung Neoplas | 2016 |
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2008 |
Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Topics: Aged; Alcohol Drinking; Analysis of Variance; Antihypertensive Agents; Atenolol; Atrial Fibrillation | 2012 |
Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Comorbidity; Double-Bl | 2012 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Captopr | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atenolol; | 2005 |
Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Female; | 2006 |
[Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Fem | 2006 |
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Drug Therapy, Combin | 2006 |
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Topics: Aged; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Double-Blind Method; Electrocardiograp | 2006 |
Comparison of rate and rhythm control in hypertension patients with atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2008 |
35 other studies available for losartan and Atrial Fibrillation
| Article | Year |
|---|---|
Angiotensin-receptor blocker losartan alleviates atrial fibrillation in rats by downregulating frizzled 8 and inhibiting the activation of WNT-5A pathway.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; A | 2023 |
Losartan inhibits hyposmotic-induced increase of IKs current and shortening of action potential duration in guinea pig atrial myocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Femal | 2020 |
Can dabigatran improve blood pressure control?
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antihypertensive Agents; Antithrombins; Atrial Fib | 2013 |
An Angiotensin receptor blocker prevents arrhythmogenic left atrial remodeling in a rat post myocardial infarction induced heart failure model.
Topics: Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Atrial Remodeling; Disease Models, A | 2013 |
Hypertension, inflammation and atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Female; Humans; Hypertension; Hypertrophy, Left Ventri | 2014 |
Does angiotensin receptor blockade ameliorate the prothrombotic tendency in hypertensive patients with atrial fibrillation? Breaking the vicious cycle.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; H | 2014 |
Blockade of brain angiotensin II type 1 receptor inhibits the development of atrial fibrillation in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; A | 2015 |
TRIF promotes angiotensin II-induced cross-talk between fibroblasts and macrophages in atrial fibrosis.
Topics: Adaptor Proteins, Vesicular Transport; Angiotensin II; Animals; Atrial Fibrillation; Cell Communicat | 2015 |
The effect of different treatment strategies on left atrial size in patients with lone paroxysmal atrial fibrillation-a prospective cohort study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; | 2008 |
Catheter ablation vs. amiodarone plus losartan for prevention of atrial fibrillation recurrence in patients with paroxysmal atrial fibrillation.
Topics: Amiodarone; Angiotensin II Type 2 Receptor Blockers; Atrial Fibrillation; Catheter Ablation; Drug Th | 2009 |
[Hypertension and the heart].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Cardiovascula | 2009 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Blood Pressure; | 2010 |
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Blood Pressure; Cardiomegaly; Echocardiography; Electrocardiography; Fema | 2010 |
Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Cells, Cultur | 2011 |
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; At | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic | 2003 |
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atenolol; Atrial Fibrillation; Clinical Trials as Topic; F | 2003 |
Effects of Losartan on acute atrial electrical remodeling.
Topics: Animals; Atrial Fibrillation; Calcium; Cardiac Pacing, Artificial; Diltiazem; Heart Conduction Syste | 2004 |
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2005 |
[A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Clinical Tria | 2005 |
Region-specific, pacing-induced changes in repolarization in rabbit atrium: an example of sensitivity to the rare.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Apamin; Atrial Fibrillation; Atropine; Calc | 2005 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bla | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
[Hypertensive patient with enlarged heart. Caution, risk of atrial fibrillation!].
Topics: Antihypertensive Agents; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, Combination; E | 2006 |
Anti-inflammatory effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Potential benefits for the prevention of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Combinations; Humans; Losartan; Perind | 2006 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Humans; Losartan | 2007 |
Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes.
Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Antihypertens | 2007 |
The effects of losartan on signal-averaged P wave in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapping; Electrocardiograp | 2008 |
[Chronic effects on the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation treated with amiodarone, segmental pulmonary vein ablation, or amiodarone plus losartan: a prospective cohort study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality | 2007 |
Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Cells, Cultured; Fibroblasts; Heart Atria; Humans; Los | 2008 |
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |